Asmaa Ali Elsayed, Eman Saif Eldeen, Marwa Abdellah Osman, Seham Abdallah Elazab
{"title":"Role of platelet rich plasma in management of diabetic peripheral neuropathy: a case-control study.","authors":"Asmaa Ali Elsayed, Eman Saif Eldeen, Marwa Abdellah Osman, Seham Abdallah Elazab","doi":"10.1007/s40477-025-01042-7","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>Diabetic Peripheral Neuropathy (DPN) is a prevalent complication of diabetes mellitus, resulting in substantial morbidity. This study assesses the effectiveness of platelet-rich plasma (PRP) in managing DPN symptoms and enhancing nerve function.</p><p><strong>Objective: </strong>To assess the therapeutic effects of ultrasound-guided perineural injection of PRP on neuropathic pain and nerve conduction parameters in patients with type 2DPN.</p><p><strong>Methods: </strong>This is a prospective, case-control trial that included 80 participants with type 2 DPN, divided into two groups: Group A (intervention) (n = 40) received ultrasound-guided perineural injections of PRP in conjunction with medical treatment. In contrast, Group B (control) (n = 40) received medical treatment alone. Participants underwent detailed medical history, general and neurological examinations, and laboratory tests. Assessments included nerve conduction studies (NCS), which were conducted at baseline and reassessed after 3 months. The modified Toronto Clinical Neuropathy Score (mTCNS) and Visual Analog Scale (VAS) for pain were measured at baseline and 1- and 3-months post-treatment.</p><p><strong>Results: </strong>Demographic and baseline clinical characteristics were analogous across groups (p > 0.05). At three months, the intervention group showed a substantial elevation in mNCV for the tibial nerves, from 38.5 ± 5.2 m/s to 45.3 ± 4.8 m/s (p < 0.001), and for the peroneal motor nerves, from 36.2 ± 4.9 m/s to 42.7 ± 5.1 m/s (p < 0.001). The mTCNS scores improved significantly from 12.4 ± 2.1 to 6.3 ± 1.8 (p < 0.001), and VAS scores decreased from 8.2 ± 1.0 to 3.5 ± 1.2 (p < 0.001). Conversely, the control group experienced a deterioration in mTCNS scores, from 12.5 ± 2.0 to 14.1 ± 2.3 (p < 0.01), and an elevation in VAS scores, from 8.1 ± 1.1 to 9.0 ± 0.9 (p < 0.05).</p><p><strong>Conclusion: </strong>PRP therapy significantly alleviates symptoms of DPN and enhances nerve function, suggesting its potential as an effective treatment option for diabetic neuropathies.</p>","PeriodicalId":51528,"journal":{"name":"Journal of Ultrasound","volume":" ","pages":""},"PeriodicalIF":1.4000,"publicationDate":"2025-07-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Ultrasound","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1007/s40477-025-01042-7","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"RADIOLOGY, NUCLEAR MEDICINE & MEDICAL IMAGING","Score":null,"Total":0}
引用次数: 0
Abstract
Background: Diabetic Peripheral Neuropathy (DPN) is a prevalent complication of diabetes mellitus, resulting in substantial morbidity. This study assesses the effectiveness of platelet-rich plasma (PRP) in managing DPN symptoms and enhancing nerve function.
Objective: To assess the therapeutic effects of ultrasound-guided perineural injection of PRP on neuropathic pain and nerve conduction parameters in patients with type 2DPN.
Methods: This is a prospective, case-control trial that included 80 participants with type 2 DPN, divided into two groups: Group A (intervention) (n = 40) received ultrasound-guided perineural injections of PRP in conjunction with medical treatment. In contrast, Group B (control) (n = 40) received medical treatment alone. Participants underwent detailed medical history, general and neurological examinations, and laboratory tests. Assessments included nerve conduction studies (NCS), which were conducted at baseline and reassessed after 3 months. The modified Toronto Clinical Neuropathy Score (mTCNS) and Visual Analog Scale (VAS) for pain were measured at baseline and 1- and 3-months post-treatment.
Results: Demographic and baseline clinical characteristics were analogous across groups (p > 0.05). At three months, the intervention group showed a substantial elevation in mNCV for the tibial nerves, from 38.5 ± 5.2 m/s to 45.3 ± 4.8 m/s (p < 0.001), and for the peroneal motor nerves, from 36.2 ± 4.9 m/s to 42.7 ± 5.1 m/s (p < 0.001). The mTCNS scores improved significantly from 12.4 ± 2.1 to 6.3 ± 1.8 (p < 0.001), and VAS scores decreased from 8.2 ± 1.0 to 3.5 ± 1.2 (p < 0.001). Conversely, the control group experienced a deterioration in mTCNS scores, from 12.5 ± 2.0 to 14.1 ± 2.3 (p < 0.01), and an elevation in VAS scores, from 8.1 ± 1.1 to 9.0 ± 0.9 (p < 0.05).
Conclusion: PRP therapy significantly alleviates symptoms of DPN and enhances nerve function, suggesting its potential as an effective treatment option for diabetic neuropathies.
期刊介绍:
The Journal of Ultrasound is the official journal of the Italian Society for Ultrasound in Medicine and Biology (SIUMB). The journal publishes original contributions (research and review articles, case reports, technical reports and letters to the editor) on significant advances in clinical diagnostic, interventional and therapeutic applications, clinical techniques, the physics, engineering and technology of ultrasound in medicine and biology, and in cross-sectional diagnostic imaging. The official language of Journal of Ultrasound is English.